



## Evaluation of the Medicines Repurposing Program

Information bulletin 12 January 2026

### CONTEXT

The Department of Health, Disability and Ageing (the Department) engaged Healthcare Management Advisors (HMA) to undertake an independent evaluation of the Medicines Repurposing Program (MRP).

The MRP aims to enhance patient access to medicines in Australia by identifying new therapeutic uses for existing medicines. The MRP offers fee waivers to sponsors for regulatory assessment by the Therapeutic Goods Administration (TGA) and consideration of subsidy by the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS).

Since the MRP opened on 1 March 2024, there have been 25 nominations, 19 of which were found unsuitable for selection, four are under assessment, and two have been selected<sup>1</sup>. Anyone can nominate a candidate for consideration by the MRP, provided it meets the eligibility requirements:

- registration on the Australian Register of Therapeutic Goods (ARTG) as a prescription medicine.
- proposition of a new and distinct indication (i.e. a different medical condition or new patient group)
- support in-principle from a relevant pharmaceutical sponsor for nomination and consideration by MRP

The fee waivers provide financial incentives anticipated to encourage sponsors to register new indications. Further details are available from the MRP webpage – [Medicines Repurposing Program | Therapeutic Goods Administration \(TGA\)](#).

### EVALUATION OBJECTIVES

The evaluation aims to assess the effectiveness of the current program in delivering the intended outcomes. Findings and recommendations from the evaluation will inform future policy direction and planning.

### PROJECT METHOD AND TIMING

The project to evaluate MRP will occur over six months. HMA will take a staged approach to the project, including a situation analysis to inform the development of an evaluation plan, and in-depth stakeholder consultation with MRP nominators and sponsors, as well as the sector more broadly.

Stakeholder consultation will occur in project Stages 3 and 4:


- Stage 3: consultation with stakeholders who have engaged with and/or have a vested interest in the MRP (e.g. TGA, nominators and sponsors of medicines nominated for repurposing, specialist medical colleges, medicine repurposing research programs), and survey of the sector (Jan–Feb 2026)
- Stage 4: Consultation with the sponsor (and/or nominator) of current or previous repurposing medicine candidates to prepare case studies (Feb 2026)

Figure 1 presents an overview of the project to evaluate the MRP.

---

<sup>1</sup> Numbers current as of 12 January 2026

Figure 1: Project approach



## CONTACT INFORMATION

### HMA

#### HMA Project Manager

Katrina Gray  
Senior Manager, Healthcare Management  
Advisors

[katrinagray@hma.com.au](mailto:katrinagray@hma.com.au)

Phone: 0405 192 438

### Department of Health, Disability and Ageing

#### Medicines Repurposing Program Manager

Jennifer Foulcher  
Assistant Director

[MRP@health.gov.au](mailto:MRP@health.gov.au)